Trial's First Global Patient Recruited in North West London
Researchers at Imperial College Healthcare NHS Trust have randomised the first global participant in the PRESTIGE-AF trial.
PRESTIGE-AF is a collaborative research project aiming to reduce the risk of further stroke in intracerebral hemorrhage survivors who also have atrial fibrillation. An intracerebral hemorrhage is a life-threatening type of stroke caused by bleeding in the brain. Atrial fibrillation is a heart condition that causes an irregular and sometimes abnormally fast heart rate.
The study, called PREvention of Stroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF), is supported by the NIHR Clinical Research Network (CRN) North West London.
Evidence collected will be used to recommend medication for stroke prevention. It is funded by the European Commission and has partner organisations in the UK, Germany, Austria, Spain, France, Italy, and Denmark.
Stroke research is vital as it is one of the largest public health challenges around the world. It is the most common cause of disability in adulthood and the second leading cause of death globally.
Sub-studies will also explore individual predictive risk modelling using brain imaging, genetic testing and other biological markers. It will also explore cognitive and psychological factors and drug adherence in patients.
